SCHEMBL22815693

SCHEMBL22815693

NC1Cc2cc(Cl)c(Cl)cc2C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 1/20 0.56
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA12 O43570 2/20 0.42
CA7 P43166 2/20 0.42
CA14 Q9ULX7 2/20 0.42
DRD2 P14416 1/20 0.42
DRD3 P35462 1/20 0.42
MAPT P10636 2/20 0.41
NFKB1 P19838 1/20 0.41
THPO P40225 1/20 0.41
HIF1A Q16665 1/20 0.41
HSD17B10 Q99714 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KDM1A O60341 1/20 0.41
SLC6A2 P23975 6/20 0.41
SLC6A4 P31645 6/20 0.41
SLC6A3 Q01959 6/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29992505 1.00 FYN (0.56) FYNCA1CA2CA12CA7
SCHEMBL29991838 0.84 FYN (0.46) FYNCA1CA2CA12CA7
SCHEMBL12269945 0.84 FYN (0.46) FYNCA1CA2CA12CA7
SCHEMBL11884613 0.84 MAPT (0.64) FYNDRD2DRD3MAPTNFKB1
SCHEMBL28600977 0.84 FYN (0.46) FYNCA1CA2CA12CA7
SCHEMBL29992052 0.84 FYN (0.46) FYNCA1CA2CA12CA7
SCHEMBL30703471 0.84 FYN (0.46) FYNCA1CA2CA12CA7
SCHEMBL29991861 0.84 FYN (0.46) FYNCA1CA2CA12CA7
Hydrochloric Acid SCHEMBL6957726 0.82 MAPT (0.62) FYNDRD2DRD3MAPTNFKB1
Hydrochloric Acid SCHEMBL6957730 0.82 MAPT (0.62) FYNDRD2DRD3MAPTNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12145929-B2 Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same NEXTGEN BIOSCIENCE CO., LTD. (KR) 2024-11-19 US disclosed
US-20240279216-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME NEXTGEN BIOSCIENCE CO., LTD. (KR) 2024-08-22 US disclosed
EP-4353720-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME Nextgen Bioscience Co., Ltd. (KR) 2024-04-17 EP disclosed
CN-117396471-A Novel piperidine derivatives and pharmaceutical compositions for inhibiting autotaxin comprising the same 株式会社次代生物科学 2024-01-12 CN disclosed
US-20230339890-A1 AMINO ALCOHOL COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. 2023-10-26 US disclosed
US-20230339890-A1 AMINO ALCOHOL COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. 2023-10-26 US disclosed
WO-2023107630-A2 AMINO ALCOHOL COMPOUNDS AND USES THEREOF Kineta, Inc. (US) 2023-06-15 WO disclosed
WO-2023107630-A2 AMINO ALCOHOL COMPOUNDS AND USES THEREOF Kineta, Inc. (US) 2023-06-15 WO disclosed
WO-2023055178-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME 주식회사 넥스트젠바이오사이언스 2023-04-06 WO disclosed
US-20220332708-A1 SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS CYTOKINETICS INC (US) 2022-10-20 US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279216-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME ENPP2, UACA, ITCH FYN 3976/4885CA1 1578/4885CA2 915/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT FYN 2070/4885CA1 1264/4885CA2 1076/4885
US-20220332708-A1 SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS TNNT2, TNNI3, MYLK2 FYN 2746/4885CA1 4057/4885CA2 597/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT FYN 2070/4885CA1 1264/4885CA2 1076/4885
US-12145929-B2 Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same ENPP2, UACA, ACAT2 FYN 4089/4885CA1 1296/4885CA2 924/4885
US-20230339890-A1 AMINO ALCOHOL COMPOUNDS AND USES THEREOF AADAT, SLC1A2, SLC1A1 FYN 1971/4885CA1 423/4885CA2 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.